Stockscreener 앱 받기
139.44
0.07%
0.0676
전일 마감가:
$139.37
열려 있는:
$139.69
하루 거래량:
1.01M
Relative Volume:
0.15
시가총액:
$172.90B
수익:
$29.45B
순이익/손실:
$8.51B
주가수익비율:
20.56
EPS:
6.7823
순현금흐름:
$9.46B
1주 성능:
+0.88%
1개월 성능:
-6.36%
6개월 성능:
+25.48%
1년 성능:
+25.33%
1일 변동 폭
$138.82
$140.84
1주일 범위
$133.89
$141.70
52주 변동 폭
$93.37
$157.29
길리어드 사이언스 Stock (GILD) Company Profile
명칭
Gilead Sciences Inc
전화
(650) 574-3000
주소
333 LAKESIDE DR, FOSTER CITY, CA
Compare GILD vs LLY, JNJ, ABBV, AZN, MRK
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
139.30 | 172.99B | 29.45B | 8.51B | 9.46B | 6.7823 |
LLY
Lilly Eli Co
|
935.45 | 821.68B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
245.32 | 588.76B | 94.19B | 26.80B | 19.70B | 11.05 |
ABBV
Abbvie Inc
|
216.12 | 384.69B | 61.16B | 4.19B | 17.82B | 2.3614 |
AZN
Astrazeneca Plc
|
199.33 | 305.86B | 58.80B | 10.24B | 8.98B | 3.2788 |
MRK
Merck Co Inc
|
120.99 | 297.40B | 64.93B | 18.26B | 12.36B | 7.2751 |
길리어드 사이언스 Stock (GILD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-10 | 개시 | Jefferies | Buy |
| 2026-02-20 | 개시 | Barclays | Equal Weight |
| 2026-02-11 | 재확인 | Needham | Buy |
| 2026-01-07 | 재개 | UBS | Buy |
| 2025-11-24 | 재개 | Truist | Buy |
| 2025-11-13 | 개시 | Scotiabank | Sector Outperform |
| 2025-08-19 | 업그레이드 | Daiwa Securities | Neutral → Outperform |
| 2025-08-08 | 업그레이드 | Truist | Hold → Buy |
| 2025-07-25 | 업그레이드 | Needham | Hold → Buy |
| 2025-04-22 | 재개 | Cantor Fitzgerald | Overweight |
| 2025-03-04 | 재확인 | Oppenheimer | Outperform |
| 2025-02-18 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2025-02-13 | 업그레이드 | DZ Bank | Hold → Buy |
| 2025-01-10 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | 재개 | BofA Securities | Buy |
| 2024-11-15 | 개시 | Wolfe Research | Outperform |
| 2024-11-14 | 개시 | Citigroup | Buy |
| 2024-11-08 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2024-10-21 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | 개시 | Bernstein | Outperform |
| 2024-10-07 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | 재확인 | Maxim Group | Buy |
| 2024-04-24 | 업그레이드 | HSBC Securities | Reduce → Hold |
| 2024-02-22 | 다운그레이드 | Truist | Buy → Hold |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-09-08 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2023-09-06 | 개시 | HSBC Securities | Reduce |
| 2023-07-24 | 재확인 | Barclays | Equal Weight |
| 2023-05-16 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | 재개 | Piper Sandler | Overweight |
| 2023-01-03 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | 재개 | BofA Securities | Neutral |
| 2022-12-09 | 다운그레이드 | DZ Bank | Buy → Hold |
| 2022-10-31 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2022-10-28 | 재확인 | BMO Capital Markets | Market Perform |
| 2022-10-28 | 재확인 | Cowen | Outperform |
| 2022-10-28 | 재확인 | JP Morgan | Overweight |
| 2022-10-28 | 재확인 | Jefferies | Buy |
| 2022-10-28 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | 재확인 | RBC Capital Mkts | Outperform |
| 2022-10-28 | 업그레이드 | Truist | Hold → Buy |
| 2022-10-28 | 재확인 | Wells Fargo | Equal Weight |
| 2022-10-04 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2022-07-13 | 개시 | Cantor Fitzgerald | Neutral |
| 2022-05-23 | 개시 | SVB Leerink | Mkt Perform |
| 2022-02-28 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | 재확인 | BMO Capital Markets | Outperform |
| 2022-02-02 | 재확인 | BofA Securities | Neutral |
| 2022-02-02 | 재확인 | RBC Capital Mkts | Outperform |
| 2022-02-02 | 재확인 | Truist | Hold |
| 2022-02-02 | 재확인 | Wells Fargo | Equal Weight |
| 2022-01-28 | 업그레이드 | Argus | Hold → Buy |
| 2022-01-06 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | 재개 | Wells Fargo | Equal Weight |
| 2021-12-06 | 개시 | Goldman | Neutral |
| 2021-11-19 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | 재개 | Piper Sandler | Neutral |
| 2021-10-20 | 재개 | Cowen | Outperform |
| 2021-07-30 | 재확인 | BMO Capital Markets | Market Perform |
| 2021-07-30 | 재확인 | RBC Capital Mkts | Outperform |
| 2021-04-01 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | 업그레이드 | Redburn | Neutral → Buy |
| 2021-01-19 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-11-03 | 재개 | Morgan Stanley | Equal-Weight |
| 2020-10-28 | 개시 | UBS | Neutral |
| 2020-09-30 | 재개 | Jefferies | Buy |
| 2020-09-15 | 업그레이드 | Maxim Group | Hold → Buy |
| 2020-07-31 | 재확인 | Credit Suisse | Neutral |
| 2020-07-31 | 재확인 | Morgan Stanley | Equal-Weight |
| 2020-07-31 | 재확인 | Piper Sandler | Overweight |
| 2020-07-31 | 재확인 | RBC Capital Mkts | Outperform |
| 2020-07-31 | 재확인 | SunTrust | Hold |
| 2020-07-31 | 재확인 | Wells Fargo | Equal Weight |
| 2020-07-20 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | 업그레이드 | SunTrust | Sell → Hold |
| 2020-05-01 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-05-01 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | 다운그레이드 | SunTrust | Hold → Sell |
| 2020-04-27 | 다운그레이드 | UBS | Buy → Neutral |
| 2020-04-20 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | 다운그레이드 | CFRA | Hold → Sell |
모두보기
길리어드 사이언스 주식(GILD)의 최신 뉴스
Gilead Sciences, Inc. $GILD Shares Acquired by Moody Lynn & Lieberson LLC - MarketBeat
Gilead Sciences, Inc. $GILD Stock Holdings Raised by Nisa Investment Advisors LLC - MarketBeat
Meyer Handelman Co. Has $41.33 Million Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Shrier Wealth Management LLC Buys Shares of 14,244 Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences (GILD) Rises Yet Lags Behind Market: Some Facts Worth Knowing - Yahoo Finance
Gilead Sciences Acquires Ouro Medicines for $2.2 Billion to Lead 'Immune Reset' Revolution - FinancialContent
Gilead Sciences Inc. stock rises Tuesday, still underperforms market - MarketWatch
Bernstein Maintains Gilead Sciences(GILD.US) With Buy Rating, Raises Target Price to $160 - Moomoo
UBS reiterates Gilead Sciences stock rating on strong Yeztugo sales - Investing.com
Gilead Sciences Inc Stock (GILD) Moved Up by 3.62% on Mar 31: A Full Analysis - TradingKey
Gilead and its new HIV prevention drug are in the sights of a well-known humanitarian group - The Business Journals
MSF denied access to Gilead HIV-prevention drug - EU Reporter
2 Defensive Dividend Payers Growing Fast on AI Demand - Investing.com
J. Safra Sarasin Holding AG Trims Gilead Sciences Stake - National Today
Gilead (GILD) Enters Agreement to Acquire Ouro Medicines - GuruFocus
J. Safra Sarasin Holding AG Has $100.57 Million Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
Boston Common Asset Management LLC Sells 15,833 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Expands Autoimmune Ambitions With Ouro Deal And Galapagos Collaboration - Yahoo Finance
Galapagos and Gilead Enter into Binding Agreement to Collaborate on Advancing First in Class T Cell Engager Program for Autoimmune Diseases - The Manila Times
Insider Sell: Daniel O'Day Sells 10,000 Shares of Gilead Sciences Inc (GILD) - GuruFocus
[Press release] Médecins Sans Frontières: Gilead refuses to sell groundbreaking HIV prevention drug to MSF - European AIDS Treatment Group
Gilead Sciences (NASDAQ: GILD) CEO sells 10,000 shares under 10b5-1 plan - Stock Titan
Gilead Sciences Inc. stock outperforms competitors on strong trading day - MarketWatch
Doctors Without Borders calls Gilead 'unconscionable' for refusing to sell HIV prevention drug to organization - statnews.com
Gilead refuses to sell groundbreaking HIV prevention drug to MSF - MSF Access
Open letter to Gilead: Prevention should not be a privilege - Doctors Without Borders
Gilead to acquire Ouro Medicines in $2.18B deal, expand inflammation pipeline - MSN
Nomura VIP Core Equity Series's Gilead Sciences Inc(GILD) Holding History - GuruFocus
Beacon Investment Advisory Services Inc. Buys 10,449 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Stake Lifted by USA Financial Formulas - MarketBeat
Wedge Capital Management L L P NC Reduces Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
Synergy Asset Management LLC Has $204,000 Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Exchange Traded Concepts LLC Raises Position in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences: Caution After A Re-Rating Amidst New Concentration Risks (NASDAQ:GILD) - Seeking Alpha
Why Gilead Sciences (GILD) Dipped More Than Broader Market Today - Yahoo Finance
Gilead: Why The 'Immune System Company' Pivot Is No Longer A Bargain (Downgrade) (GILD) - Seeking Alpha
Gilead Sciences Inc. stock underperforms Friday when compared to competitors - MarketWatch
Daniel O'Day sells shares at Gilead Sciences (NASDAQ: GILD) - Stock Titan
Gilead Sciences Inc Stock: Strong HIV Franchise and Dividend Growth Position Shares for Long-Term Va - AD HOC NEWS
Deutsche Bank reiterates Buy on Gilead Sciences stock, $155 target - Investing.com
Is Gilead (GILD) a Buy as Wall Street Analysts Look Optimistic? - Yahoo Finance
Can Gilead's Recent Acquisitions Strengthen Its Long-Term Growth Outlook? - TradingView
Fierce Pharma Asia—Takeda’s $1.3B reorg; India’s GLP-1 floodgates; Gilead’s $2.2B buy of a China NewCo - Fierce Pharma
Gilead Sciences FY2026 EPS Increased by Erste Group Bank - MarketBeat
Gilead Sciences, Inc. $GILD Shares Purchased by Global X Japan Co. Ltd. - MarketBeat
Rx Rundown: Merck, Gilead Sciences and Sanofi and more - Medical Marketing and Media
NatWest Group plc Has $5.40 Million Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences nears $2B deal for Ouro MedicinesFT - MSN
GILD Stock Price, Quote & Chart | GILEAD SCIENCES INC (NASDAQ:GILD) - ChartMill
A Look At Gilead Sciences (GILD) Valuation After Recent Share Price Weakness - simplywall.st
Gilead to Acquire Ouro Medicines in $2.18B Deal, Expand Inflammation Pipeline - Insider Monkey
길리어드 사이언스 (GILD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.01%
자본화:
|
볼륨(24시간):